Enovis CORP ENOV
- Headquarters
- Lewisville, TX
- CEO
- Damien McDonald
- Next results
- around Feb 25, 2027
Where each dollar of revenue went, FY2021
Revenue of $1.4B through the costs to a net profit of $71.7M · income statement of the 10-K
ENOV among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Critical audit matters changedNew this year: Evaluation of Goodwill Impairment (“At December 31, 2025, the Company’s goodwill allocated to the Prevention & Recovery reporting unit and Reconstructive reporting unit was $401 million and $317 million, respectively. As discussed in Note 2 to the consolidated financial statements, goodwill is not amortized, but rather is subject to a”). No longer listed: Goodwill; Valuation of intangible assets acquired in a business combination
-
Receivables +8.8% ($407.0M to $442.8M) vs revenue +6.7% ($2.1B to $2.2B), +2.1 pts apart
9 more checks with nothing to note
-
Cash from operations $217.3M vs net income −$1.2B (FY ending Dec 31, 2025)
-
Inventory +6.8% ($547.1M to $584.4M) vs revenue +6.7% ($2.1B to $2.2B), +0.1 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
4 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
Our use of artificial intelligence and machine‑learning technologies may expose us to operational, regulatory, and reputational risks. We use, and may increasingly use, artificial intelligence (“AI”) and machine‑learning technologies to support aspects of our operations, product development, and business processes. AI technologies are…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
In addition, changes in political conditions in China and changes in the state of China-U.S. relations, including any tensions relating to potential military conflict between China and Taiwan, are difficult to predict and could adversely affect our business. Furthermore, if other countries, including the United States, become further…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.6B | $1.7B | $2.1B | $2.2B |
| Net income | −$13.3M | −$33.3M | −$825.5M | −$1.2B |
| Operating cash flow | −$55.9M | $135.0M | $113.5M | $217.3M |
| Free cash flow | −$161.3M | $12.8M | −$67.2M | $19.9M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.2B ▲ 6.7% in FY2025−$1.2B in FY2025$19.9M in FY2025
Recent filings
5 filings in the last 30 days · SEC EDGAR
-
BuyNov 12, 2026Lalor Angela S (Director) bought $50K open-market purchase on Nov 10, 2026
-
BuyNov 12, 2026Wienbar Sharon L (Director) bought $50K open-market purchase on Nov 10, 2026
-
BuyNov 10, 2026Wienbar Sharon L (Director) bought $50K open-market purchase on Nov 6, 2026
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Oct 2, 2026
About the company
Enovis CORP, Lewisville, TX · from the 10-K filed Feb 26, 2026
Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion.
- Headquarters
- Lewisville, TX
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENOV/export.csv") into a cell.